Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D.

Autor: Schleiden LJ; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, 3501 Terrace St, Pittsburgh, PA, 15213, United States. Electronic address: Loren.schleiden@va.gov., Thorpe CT; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, 301 Pharmacy Lane, Chapel Hill, NC, 27599, United States., Cashy JP; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States., Gellad WF; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Division of General Internal Medicine, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Montefiore Hospital, Suite W933, Pittsburgh, PA, 5213, United States., Good CB; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, 3501 Terrace St, Pittsburgh, PA, 15213, United States; Division of General Internal Medicine, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Montefiore Hospital, Suite W933, Pittsburgh, PA, 5213, United States; Center for Value Based Pharmacy Initiatives, University of Pittsburgh Medical Center, 600 Grant St, Pittsburgh, PA, 15219, United States., Hanlon JT; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Geriatric Research Education and Clinical Center (GRECC), Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Division of Geriatric Medicine, School of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Medical Building, Suite 500, Pittsburgh, PA, 15213, United States., Mor MK; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, 130 De Soto St, Pittsburgh, PA, 15261, United States., Niznik JD; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, 3501 Terrace St, Pittsburgh, PA, 15213, United States; Division of Geriatric Medicine, School of Medicine, University of Pittsburgh, 3471 Fifth Ave, Kaufmann Medical Building, Suite 500, Pittsburgh, PA, 15213, United States., Pleis JR; National Center for Health Statistics, Centers for Disease Control and Prevention, Division of Research and Methodology, 3311 Toledo Road, Hyattsville, MD, 20782, United States., Van Houtven CH; Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, VA Medical Center (152), 508 Fulton St., Durham, NC, 27705, United States; Department of Population Health Sciences, School of Medicine, Duke University Medical Center, Imperial Center, Durham, NC, 27713, United States., Thorpe JM; Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, United States; Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, 301 Pharmacy Lane, Chapel Hill, NC, 27599, United States; Veterans Experience Center, Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Annex Suite 202, Philadelphia, PA, 19104, United States.
Jazyk: angličtina
Zdroj: Research in social & administrative pharmacy : RSAP [Res Social Adm Pharm] 2019 Jun; Vol. 15 (6), pp. 701-709. Date of Electronic Publication: 2018 Sep 08.
DOI: 10.1016/j.sapharm.2018.09.001
Abstrakt: Background: Obtaining prescription medications from multiple health systems may complicate coordination of care. Older Veterans who obtain medications concurrently through Veterans Affairs (VA) benefits and Medicare Part D benefits (dual users) are at higher risk of unintended negative outcomes.
Objective: To explore characteristics predicting dual drug benefit use from both VA and Medicare Part D in a national sample of older Veterans with dementia.
Methods: Administrative data were obtained from the VA and Medicare for a national sample of 110,828 Veterans with dementia ages 68 and older in 2010. Veterans were classified into three drug benefit user groups based on the source of all prescription medications they obtained in 2010: VA-only, Part D-only, and Dual Use. Multinomial logistic regression was used to examine predictors of drug benefit user group. The source of prescriptions was described for each of the ten most frequently used drug classes and opioids.
Results: Fifty-six percent of Veterans received all of their prescription medications from VA-only, 28% from Part D-only, and 16% from both VA and Part D. Veterans who were eligible for Medicaid or who had a priority group score conferring less generous drug benefits within the VA were more likely to be Part D-only or dual users. Nearly one fourth of Veterans taking opioids concurrently received opioid prescriptions from dual sources (24.7%).
Conclusions: Medicaid eligibility and Veteran priority group status, which largely decrease copayments for drugs obtained outside versus within the VA, respectively, were the main factors predicting drug user benefit group. Policies to encourage single-system prescribing and enhance communication across health systems are crucial to preventing negative health outcomes related to care fragmentation.
(Copyright © 2018 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: